Barclays
RVMD icon

Barclays’s Revolution Medicines RVMD Stock Holding History

Barclays’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.3M Sell
108,588
-2,590
-2% -$513K ﹤0.01% 1196
2026
Q2 		$20.8M Sell
111,178
-272,001
-71% -$39.7M ﹤0.01% 1111
2026
Q1 		$37.3M Buy
383,179
+247,131
+182% +$25M 0.01% 838
2025
Q4 		$10.8M Sell
136,048
-154,401
-53% -$10.1M ﹤0.01% 1627
2025
Q3 		$13.6M Buy
290,449
+34,065
+13% +$1.33M ﹤0.01% 1455
2025
Q2 		$9.43M Sell
256,384
-22,067
-8% -$848K ﹤0.01% 1631
2025
Q1 		$9.8M Sell
278,451
-130,163
-32% -$5.28M ﹤0.01% 1419
2024
Q4 		$17.9M Buy
408,614
+113,950
+39% +$5.75M 0.01% 1196
2024
Q3 		$13.4M Buy
294,664
+192,021
+187% +$8.36M ﹤0.01% 1289
2024
Q2 		$3.98M Sell
102,643
-32,773
-24% -$1.22M ﹤0.01% 1677
2024
Q1 		$4.36M Sell
135,416
-218,369
-62% -$6.47M ﹤0.01% 1959
2023
Q4 		$10.1M Buy
353,785
+125,124
+55% +$3.01M ﹤0.01% 1504
2023
Q3 		$6.33M Buy
228,661
+42,336
+23% +$1.26M ﹤0.01% 1193
2023
Q2 		$4.98M Buy
186,325
+38,376
+26% +$942K ﹤0.01% 1350
2023
Q1 		$3.2M Buy
147,949
+5,950
+4% +$147K ﹤0.01% 1847
2022
Q4 		$3.38M Sell
141,999
-27,918
-16% -$594K ﹤0.01% 1895
2022
Q3 		$3.35M Buy
169,917
+139,256
+454% +$3.06M ﹤0.01% 1405
2022
Q2 		$598K Sell
30,661
-7,052
-19% -$137K ﹤0.01% 2744
2022
Q1 		$962K Buy
+37,713
New +$821K ﹤0.01% 2441

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Barclays's RVMD Position: Q3 2026 in Review

Barclays reduced its Revolution Medicines (RVMD) stake by 2.3% in Q3 2026, selling an estimated $513K and leaving 108,588 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

Barclays first reported a position in RVMD in Q1 2022 and has held it in 19 quarters since. The position peaked at $37.3M in Q1 2026. 577 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Barclays held 108,588 shares of Revolution Medicines worth $22.3M as of Q3 2026.
  • Barclays sold 2,590 Revolution Medicines shares in Q3 2026, an estimated $513K.
  • Revolution Medicines made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1196 holding.
  • Barclays first reported a position in Revolution Medicines in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Revolution Medicines position peaked at $37.3M in Q1 2026.
  • 577 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.